ERG245

ERG245 is a BCAT1 inhibitor that enhances oxidative phosphorylation (OXPHOS) in CD8+ T cells by specifically inhibiting BCAT1 activity, thereby increasing the cytotoxicity of CD8+ T cells. ERG245, in combination with Pembrolizumab (anti-PD-1, HY-P9902A), promotes tumor regression. ERG245 can be used in research related to immuno-oncology[1].

Product Specifications

UNSPSC

12352005

Target

Aminotransferases (Transaminases)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/erg245.html

Purity

99.49

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC(CCC(C(C1=CC=C(Br)C=C1)=O)C2=CC=CC=C2)=O

Molecular Formula

C17H15BrO3

Molecular Weight

347.20

References & Citations

[1]Lodi F, et al. BCAT1 inhibition affects CD8+ T cell activation, exhaustion, and tumoral immunity by altering iron homeostasis[J]. bioRxiv, 2023: 2023.02. 25.530034.